SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 1, 2026	Oct 1, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
144	Sep 14, 2026	Sep 14, 2026	View filing
144	Sep 11, 2026	Sep 11, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 1, 2026	Sep 1, 2026	View filing
4	Aug 27, 2026	Aug 27, 2026	View filing
4	Aug 26, 2026	Aug 26, 2026	View filing
144	Aug 25, 2026	Aug 25, 2026	View filing
144	Aug 24, 2026	Aug 24, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
CERT	Aug 17, 2026	Aug 14, 2026	View filing
144	Aug 14, 2026	Aug 14, 2026	View filing
144	Aug 14, 2026	Aug 14, 2026	View filing
8-A12B	Aug 14, 2026	Aug 14, 2026	View filing
4	Aug 6, 2026	Aug 6, 2026	View filing
4	Aug 6, 2026	Aug 6, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
144	Jul 31, 2026	Jul 31, 2026	View filing
144	Jul 31, 2026	Jul 31, 2026	View filing
10-Q	Jul 30, 2026	Jul 30, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing

About Castle Biosciences, Inc.

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.

Friendswood, TX

1,002 employees

castlebiosciences.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Derek J. Maetzold

View full financials